Seer delivered a solid second quarter in 2025, achieving $4.1 million in revenue, a 32% increase year-over-year, primarily driven by higher product sales and service revenue. The company also launched key new products, the Proteograph ONE assay and SP200 automation instrument, enhancing platform scalability. Despite macroeconomic pressures, Seer ended the quarter with strong cash reserves and reduced operating expenses.

Seer achieved $4.2 million in revenue during Q1 2025, reflecting 37% year-over-year growth. Improved gross profit of $2.1 million and a stable cash position of $285 million highlighted the quarter, though net losses persisted at $19.9 million.

Seer reported a 10% decrease in Q4 2024 revenue to $4.0 million compared to the prior year, primarily due to lower instrument sales and no grant revenue. The company ended the year with approximately $300 million in cash, cash equivalents, and investments.

Seer, Inc. reported revenue of $4.0 million for the third quarter of 2024, a 3% decrease compared to the prior year. The company's net loss was $21.3 million. They ended the quarter with approximately $312 million in cash, cash equivalents and investments.

Seer, Inc. reported a revenue of $3.1 million for Q2 2024, a 23% decrease compared to the previous year. The company launched the Seer Technology Access Center (STAC) in Europe and ended the quarter with $344.6 million in cash, cash equivalents, and investments. They are adjusting full year revenue expectations to $13-$15 million.

Seer reported revenue of $3.1 million for the first quarter of 2024, a 24% decrease compared to the prior year. The company's net loss was $20.7 million. They ended the quarter with $359.2 million in cash, cash equivalents and investments.

Seer, Inc. reported Q4 2023 revenue of $4.4 million, a 3.6% decrease year-over-year. The net loss for the quarter was $17.8 million, compared to $22.5 million for the same period last year. The company ended the year with approximately $373 million in cash, cash equivalents, and investments.

Seer, Inc. reported a 5% increase in revenue for the third quarter of 2023, reaching $4.2 million. The increase was driven by higher instrument sales, services, and grant revenue, although this was partially offset by lower consumables sales. The company ended the quarter with $380.8 million in cash, cash equivalents, and investments but anticipates coming in at the lower half of its revenue guidance.

Seer, Inc. reported revenue of $4.0 million for Q2 2023, an 11% increase year-over-year. The company launched the Proteograph XT Assay Kit and introduced the Seer Technology Access Center (STAC). They ended the quarter with $396 million in cash, cash equivalents and investments. The company expects full year 2023 revenue to be in the range of $16 million to $18 million.

Seer, Inc. reported a 22% increase in revenue for the first quarter of 2023, reaching $4.1 million. This growth was primarily driven by increased sales of consumable kits related to the Proteograph Product Suite. The company's net loss was $24.0 million, slightly higher than the previous year. Seer reaffirms its full-year 2023 revenue guidance of $23 million to $25 million.

Seer reported a 50% increase in revenue for the fourth quarter of 2022, driven by growth in consumable and instrument sales of the Proteograph Product Suite, service projects, and lease revenue. The company's gross margin was 50% for the quarter. They anticipate revenue growth in 2023.

Seer, Inc. reported revenue of $4.0 million for the third quarter of 2022, compared to $2.2 million for the same period in 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. The net loss for the quarter was $24.0 million, compared to $18.4 million for the corresponding prior year period. Cash, cash equivalents and investments were approximately $441.0 million as of September 30, 2022.

Seer reported revenue of $3.6 million for Q2 2022, an increase compared to $1.3 million in Q2 2021. The company's gross profit was $1.6 million with a gross margin of 44%. Net loss for the quarter was $22.8 million. Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million.

Seer reported revenue of $3.3 million for the first quarter of 2022, a significant increase compared to $62 thousand in the same period last year. The company's net loss was $23.6 million, and it continues to expect full-year 2022 revenue to be in the range of $14.0 million to $16.0 million.

Seer, Inc. reported a revenue of $3.1 million for Q4 2021, a significant increase compared to the previous year. The company's net loss for the quarter was $19.7 million. Broad commercial release of the Proteograph Product Suite commenced, with multiple orders pre-booked.

Seer, Inc. reported revenue of $2.2 million for the third quarter of 2021, a significant increase from $72 thousand in the same period of 2020. This growth was primarily driven by sales of products related to the Proteograph Product Suite and services performed for a large pharmaceutical company. However, the company's operating expenses also increased substantially, leading to a net loss of $18.4 million, compared to a net loss of $8.2 million in the prior year period.